Oncolys BioPharma Inc.
Announcement of 24-Month Stability Test Results for Telomelysin® for Injection
The 24-month stability test for Telomelysin® for Injection met acceptance criteria for all quality items. The second commercial supply batch shipped in 2027 is planned to be supplied with a 24-month shelf life. A 36-month stability test report is expected in the future. Improved stability will enhance supply reliability to medical institutions.
Key Figures
- 24-month stability test results: Met acceptance criteria for all quality test items
- Timing of second commercial batch shipment: 2027
- Expected reporting of 36-month stability test results: H2 2027
AI要約
Quality and Stability Achievements
For Telomelysin® for Injection, the 24-month stability test was confirmed to meet acceptance criteria for all quality test items. This improves flexibility in inventory management and contributes to establishing a stable supply framework. Stability testing will continue going forward.
Future Shipping and Testing Plan
The second commercial batch to be shipped in 2027 is planned to be supplied with a 24-month shelf life. The 36-month stability test results are expected to be reported in H2 2027, further strengthening supply reliability and support to medical institutions.
Oncolys BioPharma Inc.
Company overview · Stock price · Financial data · All IR
